8月5日，Cencora盘中上涨3.78%，报317.86美元/股，成交额2.42亿美元。
消息面上，公司当日盘前公布第三季度财报，业绩全面超出华尔街预期。数据显示，Q3调整后每股收益4.48美元，超出市场预期的4.35美元，同比增长12%；营收847.54亿美元，高于预期的843.15亿美元。公司同步将全年调整后每股收益指引上调至17.75至17.95美元，此前为17.65至17.90美元。
此外，管理层在电话会议中明确表示，战略重心聚焦视网膜与肿瘤两大治疗领域，未来并购将围绕增值型补强式收购展开。公司此前已于3月宣布以11亿美元收购EyeSouth Partners视网膜业务，并与Kite达成CAR-T细胞疗法分销协议，持续深耕专业赛道。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.